Regeneron Pharmaceuticals annual r&d spending
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Regeneron Pharmaceuticals R&D Spending Growth & History (REGN)
Regeneron Pharmaceuticals's r&d spending was $5.85B for fiscal 2025.
View full Regeneron Pharmaceuticals company overviewRegeneron Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.85B | $718.2M | +13.99% |
| 2024 | 2024-12-31 | $5.13B | $693.0M | +15.61% |
| 2023 | 2023-12-31 | $4.44B | $846.5M | +23.56% |
| 2022 | 2022-12-31 | $3.59B | $732.4M | +25.61% |
| 2021 | 2021-12-31 | $2.86B | $213.1M | +8.05% |
| 2020 | 2020-12-31 | $2.65B | $197.0M | +8.04% |
| 2019 | 2019-12-31 | $2.45B | $981.2M | +66.80% |
| 2018 | 2018-12-31 | $1.47B | −$606.3M | −29.22% |
| 2017 | 2017-12-31 | $2.08B | $22.8M | +1.11% |
| 2016 | 2016-12-31 | $2.05B | $431.7M | +26.64% |
| 2015 | 2015-12-31 | $1.62B | $349.2M | +27.47% |
| 2014 | 2014-12-31 | $1.27B | $411.4M | +47.84% |
| 2013 | 2013-12-31 | $859.9M | $234.4M | +37.47% |
| 2012 | 2012-12-31 | $625.6M | $96.0M | +18.14% |
| 2011 | 2011-12-31 | $529.5M | $40.3M | +8.23% |
| 2010 | 2010-12-31 | $489.3M | $90.5M | +22.69% |
| 2009 | 2009-12-31 | $398.8M | $123.9M | +45.06% |
| 2008 | 2008-12-31 | $274.9M | — | — |
Regeneron Pharmaceuticals quarterly r&d spending
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.63B | $209.9M | +14.76% |
| Q1 2026 | 2026-03-31 | $1.54B | $216.1M | +16.28% |
| Q4 2025 | 2025-12-31 | $1.63B | $214.0M | +15.15% |
| Q3 2025 | 2025-09-30 | $1.48B | $203.5M | +16.00% |
| Q2 2025 | 2025-06-30 | $1.42B | $221.7M | +18.48% |
| Q1 2025 | 2025-03-31 | $1.33B | $79.0M | +6.33% |
| Q4 2024 | 2024-12-31 | $1.41B | $234.9M | +19.95% |
| Q3 2024 | 2024-09-30 | $1.27B | $196.2M | +18.25% |
| Q2 2024 | 2024-06-30 | $1.20B | $114.7M | +10.57% |
| Q1 2024 | 2024-03-31 | $1.25B | $147.2M | +13.37% |
| Q4 2023 | 2023-12-31 | $1.18B | $134.1M | +12.86% |
| Q3 2023 | 2023-09-30 | $1.08B | $164.0M | +18.00% |
| Q2 2023 | 2023-06-30 | $1.09B | $291.0M | +36.64% |
| Q1 2023 | 2023-03-31 | $1.10B | $257.4M | +30.50% |
| Q4 2022 | 2022-12-31 | $1.04B | $305.5M | +41.42% |
| Q3 2022 | 2022-09-30 | $911.3M | $245.9M | +36.96% |
| Q2 2022 | 2022-06-30 | $794.3M | $80.1M | +11.22% |
| Q1 2022 | 2022-03-31 | $843.8M | $100.9M | +13.58% |
| Q4 2021 | 2021-12-31 | $737.6M | $81.1M | +12.35% |
| Q3 2021 | 2021-09-30 | $665.4M | −$19.2M | −2.80% |
| Q2 2021 | 2021-06-30 | $714.2M | −$7.8M | −1.08% |
| Q1 2021 | 2021-03-31 | $742.9M | $159.0M | +27.23% |
| Q4 2020 | 2020-12-31 | $656.5M | $104.1M | +18.85% |
| Q3 2020 | 2020-09-30 | $684.6M | $158.6M | +30.15% |
| Q2 2020 | 2020-06-30 | $722.0M | −$163.5M | −18.46% |
| Q1 2020 | 2020-03-31 | $583.9M | $97.8M | +20.12% |
| Q4 2019 | 2019-12-31 | $552.4M | — | — |
| Q3 2019 | 2019-09-30 | $526.0M | −$31.0M | −5.57% |
| Q2 2019 | 2019-06-30 | $885.5M | $356.2M | +67.30% |
| Q1 2019 | 2019-03-31 | $486.1M | −$12.5M | −2.51% |
| Q3 2018 | 2018-09-30 | $557.0M | $27.3M | +5.14% |
| Q2 2018 | 2018-06-30 | $529.3M | $19.3M | +3.79% |
| Q1 2018 | 2018-03-31 | $498.6M | −$8.8M | −1.74% |
| Q4 2017 | 2017-12-31 | $527.9M | $48.7M | +10.17% |
| Q3 2017 | 2017-09-30 | $529.7M | −$13.3M | −2.45% |
| Q2 2017 | 2017-06-30 | $510.0M | −$50.0M | −8.92% |
| Q1 2017 | 2017-03-31 | $507.4M | $37.3M | +7.94% |
| Q4 2016 | 2016-12-31 | $479.2M | $18.0M | +3.90% |
| Q3 2016 | 2016-09-30 | $543.0M | $117.1M | +27.50% |
| Q2 2016 | 2016-06-30 | $559.9M | $169.6M | +43.45% |
| Q1 2016 | 2016-03-31 | $470.1M | $127.0M | +37.01% |
| Q4 2015 | 2015-12-31 | $461.2M | $109.5M | +31.12% |
| Q3 2015 | 2015-09-30 | $425.9M | $88.2M | +26.11% |
| Q2 2015 | 2015-06-30 | $390.3M | $95.8M | +32.54% |
| Q1 2015 | 2015-03-31 | $343.1M | $55.7M | +19.39% |
| Q4 2014 | 2014-12-31 | $351.7M | $83.6M | +31.18% |
| Q3 2014 | 2014-09-30 | $337.7M | $113.7M | +50.74% |
| Q2 2014 | 2014-06-30 | $294.5M | $107.0M | +57.10% |
| Q1 2014 | 2014-03-31 | $287.4M | $107.1M | +59.39% |
| Q4 2013 | 2013-12-31 | $268.1M | $87.1M | +48.12% |
| Q3 2013 | 2013-09-30 | $224.0M | $65.8M | +41.54% |
| Q2 2013 | 2013-06-30 | $187.5M | $40.1M | +27.20% |
| Q1 2013 | 2013-03-31 | $180.3M | $41.4M | +29.84% |
| Q4 2012 | 2012-12-31 | $181.0M | $52.0M | +40.28% |
| Q3 2012 | 2012-09-30 | $158.3M | $30.4M | +23.74% |
| Q2 2012 | 2012-06-30 | $147.4M | $4.2M | +2.95% |
| Q1 2012 | 2012-03-31 | $138.9M | $9.5M | +7.32% |
| Q4 2011 | 2011-12-31 | $129.0M | $3.8M | +3.06% |
| Q3 2011 | 2011-09-30 | $127.9M | $5.9M | +4.82% |
| Q2 2011 | 2011-06-30 | $143.1M | $18.6M | +14.96% |
| Q1 2011 | 2011-03-31 | $129.4M | $11.9M | +10.15% |
| Q4 2010 | 2010-12-31 | $125.2M | — | — |
| Q3 2010 | 2010-09-30 | $122.0M | $16.6M | +15.75% |
| Q2 2010 | 2010-06-30 | $124.5M | $30.3M | +32.15% |
| Q1 2010 | 2010-03-31 | $117.5M | — | — |
| Q3 2009 | 2009-09-30 | $105.4M | — | — |
| Q2 2009 | 2009-06-30 | $94.2M | — | — |
Regeneron Pharmaceuticals r&d spending trends
Over the last five fiscal years, Regeneron Pharmaceuticals's r&d spending increased from $2.65B to $5.85B, a change of $3.20B. The latest reported quarter, Q2 2026, shows $1.63B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regeneron Pharmaceuticals source filings ↗